VIB is an independent research institute that translates insights in biology into impactful innovations for society. Collaborating with the five Flemish universities, it conducts research in plant biology, cancer, neuroscience, microbiology, inflammatory diseases, artificial intelligence and more. VIB connects science with entrepreneurship and stimulates the growth of the Flemish biotech ecosystem. The institute contributes to solutions for societal challenges such as new methods for diagnostics and treatments, as well as innovations for agriculture.Learn more at www.vib.be.

VIB Innovation & Business

VIB is an independent research institute that translates insights in biology into impactful innovations for society. Collaborating with the five...

English (Global)

Lies Vanneste

#475569

Protealis Hosted First Soy Field Day Event in Belgium to Highlight Innovations in Northern European Soy Cultivation

European Soy Industry Gathered in Ghent, Belgium during most Northern Soy Field Event

Ghent (Belgium), 12 Sept 2024 – Protealis, a leading seed and seed technologies developer for high-performing legume crops in Europe, is pleased to announce its Field Day event, which was held today in Ghent, Belgium. The event brought together a wide range of soy experts, industry partners and customers from across Europe to showcase the ground-breaking advancements the company has made in developing high-performing soy varieties tailored for the colder northern European climate. While field days are a common practice in the seed industry, this particular event stood out as the northernmost soybean location in Europe. It underscores Protealis’ dedication to developing legume crops, such as soy, that are especially suited for colder climates.

Ghent, Belgium, September 10, 2024 – MRM Health NV, a clinical-stage biopharmaceutical company developing innovative therapeutics for inflammatory, CNS and metabolic diseases, today announced the appointment of Grégoire Franoux, M.B.A., to the newly created role of Chief Business Officer. Concurrently, the company has strengthened its Board of Directors with the appointment of industry veteran Ron Robison, M.D.

MRM Health, a VIB spin-off company, appoints Grégoire Franoux as Chief Business Officer and Adds Ron Robison to its Board of Directors

Mr. Franoux will lead the company’s business development and corporate strategy, focusing on forging strategic partnerships and driving growth. He brings 20 years of experience in strategic planning, licensing, business development and corporate finance within the biotechnology sector. He joins MRM Health from Belfius Bank, where he was spearheading Corporate Finance and Capital Markets activities in the Life Sciences sector. Prior to joining Belfius, Gregoire held senior business development positions at Oxurion, Gruenenthal GmbH and Flamel Technologies. He holds an M.S. in Biotechnology from ESIEE Paris, an M.S. in International Finance from IAE Aix-Marseille, and an Executive M.B.A. from INSEAD.

Ghent, Belgium – July 26, 2024 – Confo Therapeutics, a clinical-stage company and leader in the discovery of medicines targeting G-protein coupled receptors (GPCRs), today announced the closing of a EUR 60M Series B financing. The round was led by Ackermans & van Haaren (AvH) and included participation from additional new investors, Driehaus Capital Management and Quest for Growth (QfG), as well as existing investors, BioGeneration Ventures (BGV), Capricorn Health-tech Fund (CHF), Fund+, MINTS (University of Michigan), Perceptive Advisors, Qbic, PMV, V-Bio Ventures, VIB and Wellington Partners.

Confo Therapeutics Announces EUR 60M Series B Financing to Advance Pipeline of Novel GPCR-Modulating Therapies into Clinical Development

Ghent, Belgium – July 26, 2024 – Confo Therapeutics, a clinical-stage company and leader in the discovery of medicines targeting G-protein coupled...

Having extensive experience in the food and bio-industrial sectors, Frank van Lierde brings invaluable expertise to Protealis as the company expands its commercial footprint with innovative high yield, high protein soy varieties adopted to Northern Europe.

Protealis, a VIB spin-off company, appoints Frank van Lierde to its Board of Directors

Ghent, 2 July 2024 – VIB, Flanders’ leading life sciences research institute announces today that one of its spin-off companies, Protealis, has appointed Frank van Lierde as an independent member to its board of directors, effective as of July 1st 2024.

Proceeds used to advance Augustine's lead candidate into Phase 1/2 clinical trial in neurological diseases

Augustine Therapeutics, a VIB spin-off company, raises EUR 17 million in a first closing of series A 

Ghent, 26 June 2024 – VIB, Flanders’ leading life sciences research institute announces today that one of its spin-off companies, Augustine Therapeutics, has raised EUR 17 million (USD 18.5 million) in a first closing of series A to advance its lead candidate into a Phase 1/2 first-in-human clinical trial in 2025. The financing was led by Asabys Partners, with participation from Eli Lilly and Company, and the US-based Charcot-Marie-Tooth Research Foundation. VIB also joined the round together with other existing investors AdBio partners, V-Bio Ventures, PMV and Gemma Frisius Fund.

Jan’s entrepreneurship and experience will be very valuable additions to take the next steps in the company’s growth.

Animab announces Jan Spaas as new Chairman of the Board

Animab, a front-runner in the field of highly innovative first-in-class oral antibody solutions for unmet needs in production animals, is excited to announce Jan Spaas joined the company’s board as Chairman.

The company announces the submission of applications for its first biofungicides VALORIA™ and VIRTUOSA™

Aphea.Bio submits regulatory approval application for first biofungicides

VIB spin-off company, Aphea.Bio, a leading provider of microbial solutions for agriculture, announces the , to obtain federal approval from the United States Environmental Protection Agency (EPA). Upon registration, these biofungicides will offer farmers a sustainable, and economically viable, answer to major diseases in wheat, fruit and vegetables.

Flindr Therapeutics, a precision oncology therapeutics company, today announces a €20 million Series A financing to advance its pipeline of first-in-class, small molecule inhibitors for treatment of cancer.

Precision oncology company Flindr Therapeutics announces €20 million Series A financing to advance first-in-class small molecule inhibitors

OSS, Netherlands, 24 April 2024 – Flindr Therapeutics B.V. (“Flindr” or “the Company”), a precision oncology therapeutics company, today announces a €20 million Series A financing to advance its pipeline of first-in-class, small molecule inhibitors for treatment of cancer. V-Bio Ventures led the financing alongside other new investors Johnson & Johnson Innovation – JJDC, Inc. (JJDC), QBIC Fund, Flanders Future Tech Fund and Curie Capital, as well as existing investors Oncode Oncology Bridge Fund, Swanbridge and Brabantse Ontwikkelings Maatschappij (BOM).

MRM Health, a VIB spin-off company, reports safety and positive efficacy data in its Phase 2a Pouchitis clinical study with MH002. 

MRM Health Reports positively on Phase 2a Pouchitis  Study

MRM Health NV, a clinical-stage biopharmaceutical and VIB spin-off company developing innovative therapeutics for inflammatory, CNS and metabolic diseases, today reports positive topline results from its Phase 2a clinical trial with MH002 in the orphan disease indication Pouchitis.

The clinical research is being conducted in close collaboration with Nimble Science and the University of Calgary

MRM Health Initiates Clinical Research in Parkinson’s Disease

VIB spin-off MRM Health, a clinical-stage biopharmaceutical company, announced today that it has received regulatory and ethics committee approval to start an observational, cross-sectional clinical trial to study the role of the small intestinal microbiome in Parkinson’s Disease (PD) and to identify PD-specific microbial and metabolic fingerprints in small intestinal fluid and blood. The clinical research is being conducted in close collaboration with Nimble Science and the University of Calgary, Canada.

European Soy Industry Gathered in Ghent, Belgium during most Northern Soy Field Event

MRM Health, a VIB spin-off company, appoints Grégoire Franoux as Chief Business Officer and Adds Ron Robison to its Board of Directors

Confo Therapeutics Announces EUR 60M Series B Financing to Advance Pipeline of Novel GPCR-Modulating Therapies into Clinical Development

Protealis, a VIB spin-off company, appoints Frank van Lierde to its Board of Directors

Augustine Therapeutics, a VIB spin-off company, raises EUR 17 million in a first closing of series A

Animab announces Jan Spaas as new Chairman of the Board

Aphea.Bio submits regulatory approval application for first biofungicides

Precision oncology company Flindr Therapeutics announces €20 million Series A financing to advance first-in-class small molecule inhibitors

MRM Health Reports positively on Phase 2a Pouchitis Study

MRM Health Initiates Clinical Research in Parkinson’s Disease

Contact us

Lies Vanneste

Investor Relations Manager, VIB

Get updates in your mailbox

About VIB Innovation & Business

Contact